Mann continued: "We are pleased to report that the BloodCenter of Wisconsin, one of the nation's leading independent blood centers, has adopted our integrated blood center technologies with a strategy that combines our existing LifeTrak(R) software with IMS' enhanced products to improve collections and efficiency throughout the entire process from blood donor recruitment to hospital distribution."
Mr. Mann said Mediware's UK medication management business, JAC, also
contributed to the quarter and continues to be successful winning new
accounts and expanding product penetration with existing customers.
Domestically, Mediware added 12 new medication management sites.
Among the quarter's highlights:
-- BloodCenter of Wisconsin committed to be the first to adopt Mediware's
integrated blood center technology strategy.
-- Addition of 17 new domestic customer sites.
-- Free cash flow, excluding the IMS acquisition, was $6.8 million for the
first 9-months of fiscal 2008, compared to $1.8 million in the prior
-- Service and support revenues increased to $7.2 million primarily as a
result of increased implementation services associated with blood
management sales from previous quarters.
-- Service and support backlog remains strong at approximately $24.5
-- Mediware executed a stock buy-back program, repurchasing 549,342 shares
for $3.3 million.
-- The launch plan for the new biologics management product is on track
for a June 2008 release, and product teams are actively marketing and
"We projected 2008 to be a year of transition as we reset sales
pipelines and introduce new products to drive growth," said Mann. "Through
the introduction of MediREC(TM), BloodSafe(TM), BiologiCare(TM), and our
integrated blood center solutions, we are well positioned for the coming
quarters. Overall, I
|SOURCE Mediware Information Systems, Inc.|
Copyright©2008 PR Newswire.
All rights reserved